910 CLOPPER ROAD, GAITHERSBURG, MD
Announces First Quarter 2026 Financial Results and Business Update
Altimmune, Inc. Enters Underwriting Agreement for $192.75 Million Offering
Altimmune, Inc. Amends Certificate of Incorporation to Increase Shares
Annual Report to Security Holders
Other Events
Altimmune, Inc. Enters Securities Purchase Agreement for $12.4M Offering
48 - Week IMPACT Phase 2b Topline Data Presentation December 2025
Announces CEO Transition and Succession Plan
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence